Savara Inc. announced that Dave Lowrance, Chief Financial Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. Robert Lutz, M.B.A., the Company's Chief Operating Officer, will assume the additional role of Chief Financial Officer. Mr. Lutz has served as Savara?s Chief Operating Officer since February 2023.

He brings more than two decades of operational leadership experience in the pharmaceutical industry, including experience with finance strategy, equity and debt raises, financial planning and analysis, investor relations, business development deal execution, and commercial/operational business analytics. Prior to joining Savara, Mr. Lutz served as Chief Financial and Business Officer of iBio Inc., and prior to that as Chief Financial and Business Officer of Strongbridge Biopharma plc. Earlier in his career, Mr. Lutz held leadership roles of increasing responsibility at Shire Plc.

and Cinergy Corp. and began his career as a Financial Analyst at Goldman Sachs. Mr. Lutz holds a B.A. in Economics and Computer Science from Amherst College and an M.B.A. from the Kellogg School of Management.